InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,408.40
(
0.00%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.63
(
-0.08%
)
Bitcoin
65,873.00
(
1.39%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

JJM760

Send PM Follow Ignore
Followers 5
Posts 993
Boards Moderated 0
Alias Born 06/15/2010

JJM760

Re: biomaven0 post# 14877

Monday, 12/12/2011 11:26:05 AM

Monday, December 12, 2011 11:26:05 AM

Post# of 80490

That's always been the view of the top thought leaders in this space. How much it will trickle down to general practice is a different question



And then just how much providers will approve it after Gleevec goes generic is another. Merrill today modeled $400 mil in peak sales in 2016. Barclays recently came out with their opinion and used $1.8 bil. Complete wild card as to what will ultimately become of Ponatinib in the first line.

Between that and 113, it should be an interesting few years to say the least.



Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up